2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-EP02.20

EP02.20 - Sundeep Atluri

Pdf Summary

This study investigates the impact of the timing of durvalumab initiation on progression-free survival (PFS) in patients with unresectable stage III non-small-cell lung cancer (NSCLC) who received the treatment after chemoradiotherapy (CXRT) at LSU Health Shreveport. The retrospective observational study included data from 102 patients from 2019 to 2024, using cox proportional hazards regression to analyze time-to-event data. The study primarily sought to evaluate any differences in PFS between patients starting durvalumab within 42 days or later.<br /><br />Results showed that the estimated 5-year PFS was 54% for those starting durvalumab at 42 days compared to 34% for those initiated later. However, the study found no statistically significant difference in PFS outcomes between the two groups (HR: 0.89, 95% CI: 0.45 - 1.69; p 0.68). It was noted that stage IV lung cancer patients had significantly worse PFS (HR: 3.68, 95% CI: 1.29 - 9.24, p 0.008). Furthermore, PFS was not affected by sex or PD-L1 status differences.<br /><br />The study thus concludes no significant difference in PFS between those starting durvalumab within six weeks post-CXRT versus starting later. However, it acknowledges the necessity for larger studies, be they observational or pooled, to ascertain the outcomes comprehensively and establish the best timing for durvalumab initiation following CXRT. The study underscores the requirement for further research to calculate overall survival outcomes in such patient populations.<br /><br />The context is derived from the PACIFIC trial's methodology, which initiated durvalumab within 6 weeks post the finishing of chemoradiotherapy, and underscores the need for additional information regarding outcomes when treatment starts later, an area where data is currently sparse.

Keywords

durvalumab

progression-free survival

non-small-cell lung cancer

chemoradiotherapy

timing of initiation

retrospective observational study

cox proportional hazards regression

LSU Health Shreveport

PACIFIC trial

overall survival outcomes